tbuckley/cabot-search huggingface dataset:
Implementation of a Public Lymphoma Clinic in a Private Hospital in Brazil: Challenges and Impact of Delayed Diagnosis in Patients with Diffuse Large B Cell Lymphoma
Authors: Guilherme Fleury Perini, Larissa LC Teixeira, Carolina Feres, Mariana Nassif Kerbauy, Leonardo Javier Arcuri, Denise Cunha Pasqualin, Alanna MPS Bezerra, Diogo DG Bugano, Nelson Hamerschlak
Journal: Blood (2020)
Molecular insights into probiotic mechanisms of action employed against intestinal pathogenic bacteria
Authors: Winschau F. van Zyl, Shelly M. Deane, Leon M.T. Dicks
Journal: Gut Microbes (2020)

Gastrointestinal (GI) diseases, and in particular those caused by bacterial infections, are a major cause of morbidity and mortality worldwide. Treatment is becoming increasingly difficult due to the increase in number of species that have developed resistance to antibiotics. Probiotic lactic acid bacteria (LAB) have considerable potential as alternatives to antibiotics, both in prophylactic and therapeutic applications. Several studies have documented a reduction, or prevention, of GI diseases by probiotic bacteria. Since the activities of probiotic bacteria are closely linked with conditions in the host's GI-tract (GIT) and changes in the population of enteric microorganisms, a deeper understanding of gut-microbial interactions is required in the selection of the most suitable probiotic. This necessitates a deeper understanding of the molecular capabilities of probiotic bacteria. In this review, we explore how probiotic microorganisms interact with enteric pathogens in the GIT. The significance of probiotic colonization and persistence in the GIT is also addressed.
Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial
Authors: Raphael Itzykson, Valeria Santini, Cendrine Chaffaut, Ades Lionel, Sylvain Thepot, Aristoteles Giagounidis, Margot Morabito, Nathalie Droin, Michael Luebbert, Rosa Sapena, Stanislas Nimubona, Jean E. Goasguen, Eric Wattel, Gina Zini, Jose Miguel Torregrosa Diaz, Ulrich Germing, Anna Maria Pelizzari, Sophie Park, Nadja Jaekel, Georgia Metzgeroth, Francesco Onida, Robert Navarro, Andrea Patriarca, Aspasia Stamatoulas Bastard, Martin Puttrich, Sandra Mossuto, Eric Solary, Silke Gloaguen, Sylvie Chevret, Fatiha Chermat, Uwe Platzbecker, Pierre Fenaux
Journal: Blood (2020)
Zrsr2 Deficient Zebrafish Display Hematopoietic Defects and U12-Type Intron Retention in mRNA Processing Genes
Authors: Rachel N. Weinstein, Elizabeth Broadbridge, Kevin Bishop, Blake Carrington, Kai Yu, Abdel G. Elkahloun, WeiWei Wu, Wuhong Pei, Shawn M. Burgess, Paul P. Liu, Erica Bresciani, Raman Sood
Journal: Blood (2020)
Abstract 15280: Understanding Coronary Heart Disease Experience Among Chinese Immigrants Living in Australia: A Social-Ecological Analysis
Authors: Kai Jin, Lis Neubeck, Ding Ding, Fung Koo, Janice Gullick
Journal: Circulation (2017)

Introduction: Health disparities among immigrants are known to exist across a range of socio-ecological domains. While Chinese immigrants have increased risk of coronary heart disease (CHD) after m...
Combination of Cord Blood T Regulatory Cells with Ruxolitinib Decreases Side Effects and Improves Survival in Xenogenic Graft Vs. Host Disease
Authors: Ke Zeng, Meixian Huang, Li Li, Mi-Ae Lyu, Hongbing Ma, Mitsutaka Nishimoto, Tara Sadeghi, Sairah Ahmed, Borje S. Andersson, Simrit Parmar
Journal: Blood (2020)
The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS
Authors: V. Koneti Koneti Rao, Patrick P. Ng, Craig M. Hill, Richard A. Miller, Joseph J. Buggy, James W. Janc
Journal: Blood (2020)
Prevalence and Predictors of Neurocognitive Impairment in Long-Term Survivors of Childhood Hodgkin Lymphoma: A Report from the Childhood Cancer Survivor Study
Authors: Annalynn M Williams, Mengqi Xing, Sedigheh Mirzaei Salehabadi, Yutaka Yasui, Matt J. Ehrhardt, Rebecca M Howell, Kevin C Oeffinger, Todd Gibson, Eric Chow, Wendy Leisenring, Deokumar Srivastava, Leslie L. Robison, Gregory T Armstrong, Kevin R. Krull
Journal: Blood (2020)
Abstract MP163: Renal Sympathetic Denervation (RDN) Improves Exercise Performance and Vascular Function in the Setting of Cardiometabolic HFpEF
Authors: Hunter Hidalgo, Juan Gao, Zhen Li, Thomas E Sharp, Huijing Xia, Daniel R Kapusta, Traci T Goodchild, David J Lefer
Journal: Circulation Research (2020)

Background: Heart failure with preserved ejection fraction (HFpEF) has emerged as a subclass of heart failure for which there are no effective treatments. HFpEF is induced in a large number of patients by central obesity, metabolic syndrome, and sustained activation of the sympathetic nervous system (SNS). Methods: We examined the effects of RDN in a clinically relevant model of HFpEF. The ZSF1-Obese rat exhibits the key components of cardiometabolic HFpEF including hypertension and diabetes. At 20 wks of age, ZSF1-Obese rats underwent bilateral radiofrequency RDN (RF-RDN) or sham RF-RDN and were followed for 6 weeks. LV function, blood pressure, LVEDP, vascular function, myocardial fibrosis, metabolic profiling, and exercise capacity were evaluated. We also assessed mitochondrial function of cardiac and skeletal muscle. Results: RF-RDN resulted in significant improvements in LV diastolic function, vascular relaxation, and exercise capacity. Significant reductions in blood pressure and LVEDP were observed following RF-RDN treatment. RF-RDN ameliorated cardiac fibrosis while improving cardiac and skeletal muscle mitochondrial function. We did not observe any effects of RF-RDN on the metabolic status of the ZSF-1 rat. Conclusion: Our data suggest that RF-RDN is a viable treatment option for cardiometabolic HFpEF through halting renal SNS hyperactivation and enhancing mitochondrial function to exert beneficial effects on the heart and circulation.
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
Authors: Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Allison Jones, Youn H. Kim, Neha Mehta-Shah, Elise A. Olsen, Barbara Pro, Saurabh A. Rajguru, Sima Rozati, Jonathan Said, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, Hema Sundar
Journal: Journal of the National Comprehensive Cancer Network (2020)

Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.
The Baf Subunit Dpf2 Regulates Resolution of Inflammation By Controlling Macrophage Differentiation Transcription Factor Networks
Authors: Gloria Mas Martin, Na Man, Daniel Karl, Concepcion Martinez, Stephanie Duffort, Hidehiro Itonaga, Adnan K Mookhtiar, Daniel Bilbao, Kranthi Kunkalla, Alfredo M Valencia, Clayton Collings, Cigall Kadoch, Francisco Vega, Scott C. Kogan, Stephen Nimer
Journal: Blood (2020)
Multidimensional Vascular Evaluation in Patients Treated with Tyrosine Kinase Inhibitors (TKIs): From Plaque Formation to Evolution and Follow up on 150 Patients
Authors: Elisabetta Abruzzese, Rossana Gloria, Andrea Siani, Carla Mazzone, Matteo Molica, Teresa Dentamaro, Luca Cupelli, Malgorzata Monika Trawinska, Paolo De Fabritiis
Journal: Blood (2020)
Post-Treatment Clone Size Predicts Survival Independently of IPSS-R and Response after Azacitidine Therapy for MDS.
Authors: Yasuhito Nannya, Magnus Tobiasson, Shinya Sato, Elsa Bernard, Maria Creignou, Lanying Zhao, June Takeda, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Hisashi Tsurumi, Senji Kasahara, Masataka Taguchi, Akifumi Kondo Takaori, Kazuma Ohyashiki, Hideki Makishima, Kenichi Yoshida, Tomoki Naoe, Satoru Miyano, Yasushi Miyazaki, Elli Papaemmanuil, Eva Hellstrom Lindberg, Seishi Ogawa
Journal: Blood (2020)
Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial
Authors: Stephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Henry Chan, Jie Jin, Pier Luigi Zinzani, Peter Browett, Morton Coleman, Magdalena Sobieraj-Teague, Xiaoyan Ke, Mingyuan Sun, Robert Marcus, Craig A. Portell, Keshu Zhou, Catherine Thieblemont, Melannie Co, Weige Wang, Chris Tankersley, Wenxiao Zhou, Massimo Cappellini, Jane Huang, Judith Trotman
Journal: Blood (2020)
Fetal Inactivation of the Nuclear Interacting SET Domain Protein 1 Impairs Terminal Erythroid Maturation and Results in Acute Erythroleukemia in Mice
Authors: Katharina Leonards, Marwa Almosailleakh, Samantha Tauchmann, Helene Mereau, Sabine Juge, Matheus Filgueira Bezerra, Susanne Kasper, Robert Ivanek, Alexandar Tzankov, Antoine HFM Peters, Juerg Schwaller
Journal: Blood (2017)
Abstract 411: Absence of Sexual Dimorphism in Isoproterenol-induced Cardiac Dysfunction in C57BL/6 Mice
Authors: Marianne K Grant, Davis Seelig, Ibrahim Abdelgawad, Beshay Zordoky
Journal: Circulation Research (2020)

Sex-related differences in cardiovascular diseases are complex and highly context-dependent. The objective of this work was to comprehensively determine key sex differences in the response to acute and chronic adrenergic stimulation in C57Bl/6 mice. In the current work, there was no statistically significant difference in key echocardiographic parameters between male and female C57Bl/6 mice in response to acute adrenergic stimulation (a single sub-cutaneous dose of isoproterenol 10 mg/kg). After chronic adrenergic administration (sub-cutaneous injections of isoproterenol 10 mg/kg/day for 14 days), there was similar degree of cardiac dysfunction, cardiac hypertrophy, and myocardial fibrosis in male and female mice. Similarly, chronic isoproterenol administration induced hypertrophic and fibrotic genes in hearts of male and female mice to the same extent. Intriguingly, gonadectomy of male and female mice did not have a significant impact on isoproterenol-induced cardiac dysfunction as compared to sham-operated animals. In conclusion, the current work demonstrated lack of sex-related differences in isoproterenol-induced cardiac hypertrophy, dysfunction, and fibrosis in C57Bl/6 mice. This study challenges the conventional dogma of the detrimental cardiovascular effects of male sex hormones and the beneficial effects of female sex hormones.
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The Pethema Registry Experience
Authors: Jorge Labrador, Miriam Saiz-Rodríguez, Maria Dunia De Miguel, María Belén Vidriales, Manuel Perez Encinas, Maria Jose Sanchez, Rebeca Cuello, Alicia Roldán Pérez, Susana Vives, Gonzalo Benzo Callejo, Mercedes Colorado Araujo, María García-Fortes, Maria Jose Sayas, Carmen Olivier, Isabel Recio, Diego Conde Royo, Alvaro Bienert Garcia, Maria Vahi, Carmen Muñoz García, Cristina Seri, Mar Tormo, Ferran Vall-llovera, Maria Angeles Foncillas, David Martínez-Cuadron, Miguel A. Sanz, Pau Montesinos
Journal: Blood (2020)
Clinical and immunological follow-up of very long-term kidney transplant recipients treated with calcineurin inhibitors indicates dual phenotypes
Authors: Amaury Dujardin, Mélanie Chesneau, Florian Dubois, Richard Danger, Linh Bui, Clarisse Kerleau, Pierrick Guérif, Sophie Brouard, Jacques Dantal
Journal: Kidney International (2020)
Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia
Authors: Jean Jacques Kiladjian, Uwe Platzbecker, Jiri Mayer, Árpád Illés, Witold Prejzner, Tomasz Wozny, Nikolay Tzvetkov, Alessandro M. Vannucchi, Ilya Kirgner, Zsolt Nagy, Sebastian Grosicki, Åsa Rangert Derolf, Mihaela Lazaroiu, Sung-Soo Yoon, Yeow Tee Goh, Nikolas Von Bubnoff, Srdan Verstovsek, Barbara Jane Klencke, Rafe Donahue, Ruben Mesa
Journal: Blood (2020)
Inflammation Drives Coagulopathies in Sars-Cov-2 Patients
Authors: Martha MS Sim, Meenakshi Banerjee, Melissa Hollifield, Hammodah Alfar, Xian Li, Alice Thornton, James Z Porterfield, Jamie Sturgill, Gail A Sievert, Marietta Barton-Baxter, Kenneth S Campbell, Jerold G Woodward, Sidney W Whiteheart, Beth A Garvy, Jeremy P Wood
Journal: Blood (2020)
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis
Authors: William J. Sandborn, Laurent Peyrin-Biroulet, Daniel Quirk, Wenjin Wang, Chudy I. Nduaka, Arnab Mukherjee, Chinyu Su, Bruce E. Sands
Journal: Clinical Gastroenterology and Hepatology (2020)

Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). The efficacy and safety of tofacitinib were demonstrated in a dose-ranging phase 2 induction trial, 3 phase 3 randomized, placebo-controlled trials (OCTAVE Induction 1 and 2; and OCTAVE Sustain), and an ongoing, open-label, long-term extension trial (OCTAVE Open) in patients with moderately to severely active UC. Here, we assessed short- and long-term efficacy and safety of extended induction (16 weeks) with tofacitinib 10 mg twice daily (BID) in patients who failed to respond to initial induction (8 weeks) treatment.In patients who achieved a clinical response following extended induction (delayed responders), the efficacy and safety of tofacitinib were evaluated up to Month 36 of OCTAVE Open.52.2% of patients who did not achieve clinical response to 8 weeks' treatment with tofacitinib 10 mg BID in the induction studies achieved a clinical response following extended induction (delayed responders). At Month 12 of OCTAVE Open, 70.3%, 56.8%, and 44.6% of delayed responders maintained clinical response and achieved endoscopic improvement and remission, respectively. Corresponding values at Month 36 were 56.1%, 52.0%, and 44.6%. The safety profile of the subsequent 8 weeks was similar to the initial 8 weeks.Overall, the majority of patients achieved a clinical response after 8 or 16 weeks' induction therapy with tofacitinib 10 mg BID. Tofacitinib 10 mg BID, administered as induction therapy for up to 16 weeks, had a comparable safety profile to 8 weeks' induction therapy. Most delayed responders at Month 36 were in remission.gov: NCT00787202; NCT01465763; NCT01458951; and NCT01470612.
Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial
Authors: Annette von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan U. Lattimore, Frank W.G. Leebeek, Wolfgang A. Miesbach, Michael Recht, Esteban Gomez, Robert Gut, Steven W. Pipe
Journal: Blood (2020)
Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy
Authors: Agnieszka Beata Malczewski, Severine Navarro, Jermaine Ig Coward, Natkunam Ketheesan
Journal: Journal for ImmunoTherapy of Cancer (2020)

Cancer immunotherapy with checkpoint blockade has become standard of care treatment for numerous cancer types. Despite this, robust predictive biomarkers are lacking. There is increasing evidence that the host microbiome is a predictor of immunotherapy response, although the optimal host microbiome has not been defined. Metabolomics is a new area of medicine that aims to analyze the metabolic profile of a biological system. The microbiome-derived metabolome (fecal and serum) represents the end products of microbial metabolism and these may be functionally more important than the distinct bacterial species that comprise a favorable microbiome. Short-chain fatty acids (SCFA) are metabolites produced by gut microbiota and have a role in T cell homeostasis, including differentiation of regulatory T cells. Recent studies have confirmed differential expression of SCFA for immunotherapy responders compared with non-responders. We propose that the microbiome metabolome, with a focus on SCFA may be a novel predictive biomarker for immunotherapy efficacy.
Carbon nitride-based nanocaptor: An intelligent nanosystem with metal ions chelating eﬀect for enhanced magnetic targeting phototherapy of Alzheimer's disease
Authors: Ling Gong, Xing Zhang, Kezhen Ge, Yiming Yin, Jeremiah Ong'achwa Machuki, Yun Yang, Hengliang Shi, Deqin Geng, Fenglei Gao
Journal: Biomaterials (2020)
Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial
Authors: Rubén Andújar-Espinosa, Lourdes Salinero-González, Fátima Illán-Gómez, Manuel Castilla-Martínez, Chunshao Hu-Yang, Francisco José Ruiz-López
Journal: Thorax (2020)

The relationship between asthma and vitamin D deficiency has been known for some time. However, interventional studies conducted in this regard have shown conflicting results.To evaluate the efficacy of vitamin D supplementation in asthmatic patients in improving the degree of control of asthma.Randomised, triple-blind, placebo-controlled, parallel-group study in adult asthmatic patients with serum 25-hydroxyvitamin-D3 <30 ng/mL. The intervention group received oral supplementation with 16 000 IU of calcifediol per week, and the control group had placebo added to their usual asthma treatment. The study period was 6 months. The primary endpoint was the degree of asthma control as determined by the asthma control test (ACT). Secondary endpoints included quality of life measured using the mini Asthma Quality of Life Questionnaire, the number of asthma attacks, oral corticosteroid cycles, the dose of inhaled corticosteroids, number of emergency visits, unscheduled consultations with the primary care physician and hospitalisations for asthma.One hundred and twelve patients were randomised (mean age 55 years, with 87 (78%) being women). Of the 112 patients, 106 (95%) completed the trial. Half the patients (56) were assigned to the intervention group and the other half to the control group. A statistically significant clinical improvement was observed in the intervention group (+3.09) compared with the control group (-0.57) (difference 3.66 (95% CI 0.89 to 5.43); p<0.001) as measured using ACT scores. Among the secondary endpoints, a significant improvement in the quality of life was found in the intervention group (5.34), compared with the control group (4.64) (difference 0.7 (95% CI 0.15 to 1.25); p=0.01).Among adults with asthma and vitamin D deficiency, supplementation with weekly oral calcifediol compared with placebo improved asthma control over 6 months. Further research is needed to assess long-term efficacy and safety.NCT02805907.
Searching collaborative agents for multi-plane localization in 3D ultrasound
Authors: Xin Yang, Yuhao Huang, Ruobing Huang, Haoran Dou, Rui Li, Jikuan Qian, Xiaoqiong Huang, Wenlong Shi, Chaoyu Chen, Yuanji Zhang, Haixia Wang, Yi Xiong, Dong Ni
Journal: Medical Image Analysis (2021)
All-Trans-Retinoic Acid Prevents Carfilzomib-Induced Cardiotoxicity By Decreasing Activation of the Renin-Angiotensin System
Authors: Max A Mendez, Andrej Besse, Bogdan I. Florea, Christian Zuppinger, Herman S. Overkleeft, Lenka Besse, Christoph Driessen
Journal: Blood (2020)
Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant <i>IDH1</i> AML: Results from Matched Comparisons to Historical Controls
Authors: Peter Paschka, Hervé Dombret, Xavier Thomas, Christian Recher, Sylvain Chantepie, Pau Montesinos Fernandez, Evelyn Acuña-Cruz, Paresh Vyas, Karl-Anton Kreuzer, Michael Heuser, Klaus H. Metzeler, Michael Dennis, Bruno Quesnel, Mathilde Hunault-Berger, Mohamad Mohty, Arnaud Pigneux, Stephane De Botton, Daniela Weber, Konstanze Döhner, Gary Milkovich, John Reitan, Sarah C MacDonald, Deborah Casso, Michael Storm, Hua Liu, Stephanie M. Kapsalis, Eyal C. Attar, Thomas Winkler, Hartmut Döhner
Journal: Blood (2020)
Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351
Authors: Meagan A. Jacoby, Laura E. Finn, Ashkan Emadi, Nakhle S. Saba, Bayard L. Powell, Karen P. Seiter, Rosella Garcia, Stefan Faderl, Heather J. Male
Journal: Blood (2020)
Abstract 407: Beta-blockers Reverse Beta Adrenergic Receptors Desensitization Under Hypoxia
Authors: Yu Sun, Manveen K Gupta, Kate Stenson, Sathyamangla Prasad
Journal: Circulation Research (2020)

Hypoxia to heart or brain is a primary cause of heart failure or stroke. Studies have shown that hypoxia increases the beta-adrenergic receptors (βARs) phosphorylation and dysfunction (Cheong et. al., 2016). These observations provide evidence that βARs can directly be regulated by hypoxia but less is known about the underlying mechanisms. We postulated that hypoxia shifts the homeostasis between kinase and phosphatase driven mechanisms may underlie βAR dysfunction. β2AR HEK 293 cells were exposed to hypoxia (2% O 2 ) and assessed the mechanisms underlying desensitization (G-protein coupled receptor kinases, GRKs) and resensitization (Protein phosphatase 2A, PP2A). Six hours of hypoxia treatment resulted in increase of βAR phosphorylation and GRK2 expression, and interestingly, the internalization of phosphorylated β2AR is β-arrestin independent. Assessment of βAR phosphorylation in the plasma membrane and endosomal fractions surprisingly, showed marked increase in β2AR phosphorylation in the endosomal fraction. Furthermore, we also observed that receptor associated PP2A activity was inhibited in the endosomes following hypoxia with minimal changes of activity at the plasma membranes. At the same time, PI3Kγ activity markedly upregulated in the endosomes along with an increase of I2PP2A phosphorylation. Similarly subjecting normal mice to 20 hours of hypoxia resulted in significant cardiac dysfunction (% FS: Normoxia 38.83% vs. Hypoxia 32.38%, P=0.0055; % EF: Normoxia 69.71% vs. Hypoxia 60.76%,P=0.0105) and was associated with significant increase in β2AR phosphorylation associated with significant loss in βAR function as measured by G-protein coupling adenylyl cyclase activity. Given that β-blockers confer beneficial effects, we tested whether β-blocker (propranolol) would prevent βARs phosphorylation under hypoxia or normoxia. Consistently, β-blocker treatment in normoxia results in increased β2AR phosphorylation however, remarkably β-blocker treatment in hypoxia results in loss of β2AR phosphorylation, reduction in GRK2 expression and increase in βAR-associated PP2A. These studies show that agonist-independent hypoxia-driven β2AR dysfunction can be ameliorated by β-blockers and the underlying mechanisms for this unexpected findings will be discussed in the presentation. These findings have significant clinical implications as understanding these mechanisms could provide novel insights into the benefits provided by β-blockers.
Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)
Authors: Yaya Chu, Julie-An Talano, Lee Ann Baxter-Lowe, Carolyn A. Keever-Taylor, Erin Morris, Harshini Mahanti, Janet Ayello, Bryon Johnson, Rona Singer Weinberg, Qiuhu Shi, Theodore B. Moore, Sandra Fabricatore, Brenda J. Grossman, Carmella van de Ven, Shalini Shenoy, Mitchell S Cairo
Journal: Blood (2020)